 | • レポートコード：MRC2204A042 • 出版社/出版日：Transparency Market Research / 2022年2月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、世界のコンパニオン診断市場について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、疾患別（乳がん、肺がん、大腸がん、胃がん、黒色腫）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のコンパニオン診断市場規模：疾患別（乳がん、肺がん、大腸がん、胃がん、黒色腫） ・世界のコンパニオン診断市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Companion Diagnostics Market – Scope of Report
TMR’s report on the global companion diagnostics market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides the overall revenue of the global companion diagnostics market for the period 2017–2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global companion diagnostics market for the forecast period.
The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global companion diagnostics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the global companion diagnostics market.
The report comprises an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global companion diagnostics market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global companion diagnostics market. The next section of the companion diagnostics market report highlights the USPs, which include COVID-19 pandemic impact on industry (value chain and short/mid/long term impact), recent approval of companion diagnostics for cancer care, disease prevalence & incidence rate of cancer, key mergers & acquisitions, regulatory scenarios across globe, overview of personalized medicine, and Porters Five Forces analysis.
The report delves into the competitive landscape of the global companion diagnostics market. Key players operating in the global companion diagnostics market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the companion diagnostics market in the report.
Key Questions Answered in Global Companion Diagnostics Market Report
What are the sales/revenue generated by companion diagnostics products across the globe during the forecast period?
What are the key trends in the global companion diagnostics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which segment will generate the highest revenue in 2028 and which segment will grow at the highest CAGR during the forecast period?
Which is the most attractive market in terms of indication and region during 2021–2028?
List of different companies operating in the market in 2020
Companion Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global companion diagnostics market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global companion diagnostics market. It is followed by market introduction, market dynamics, and an overview of the global companion diagnostics market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the global companion diagnostics market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
Revenue generated by key product manufacturers has been mapped to ascertain the size of the global companion diagnostics market in terms of value. The forecast presented here assesses the total revenue generated in the global companion diagnostics market. In order to provide an accurate forecast, we initiated by sizing up the current companion diagnostics market with the help of the parent market at global level.
The report analyzes the global companion diagnostics market in terms of indication and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2028 has been provided. These valuable insights would help stakeholders in making informed business decisions for investments in the global companion diagnostics market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Companion Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Companion Diagnostics Market Analysis and Forecast, 2017–2028
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Recent Approval of Companion Diagnostics for Cancer Care
5.2. Disease Prevalence & Incidence rate of Cancer
5.3. Key Mergers & Acquisitions
5.4. Regulatory Scenarios across globe
5.5. Overview of Personalized Medicine
5.6. Porters Five Forces Analysis
5.7. COVID-19 pandemic impact on the Global Companion Diagnostics Market
6. Global Companion Diagnostics Market Analysis and Forecast, by Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2028
6.3.1. Breast Cancer
6.3.2. Lung Cancer
6.3.3. Colorectal Cancer
6.3.4. Gastric Cancer
6.3.5. Melanoma
6.3.6. Others (HIV, Thalassemia)
6.4. Market Attractiveness Analysis, by Type
7. Global Companion Diagnostics Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Companion Diagnostics Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Type, 2017–2028
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Colorectal Cancer
8.2.4. Gastric Cancer
8.2.5. Melanoma
8.2.6. Others (HIV, Thalassemia)
8.3. Market Value Forecast, by Country, 2017–2028
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Indication
8.4.2. By Country
9. Europe Companion Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017–2028
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Colorectal Cancer
9.2.4. Gastric Cancer
9.2.5. Melanoma
9.2.6. Others (HIV, Thalassemia)
9.3. Market Value Forecast, by Country/Sub-region, 2017–2028
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Indication
9.4.2. By Country/Sub-region
10. Asia Pacific Companion Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2028
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Colorectal Cancer
10.2.4. Gastric Cancer
10.2.5. Melanoma
10.2.6. Others (HIV, Thalassemia)
10.3. Market Value Forecast, by Country/Sub-region, 2017–2028
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Indication
10.4.2. By Country/Sub-region
11. Latin America Companion Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2028
11.2.1. Breast Cancer
11.2.2. Lung Cancer
11.2.3. Colorectal Cancer
11.2.4. Gastric Cancer
11.2.5. Melanoma
11.2.6. Others (HIV, Thalassemia)
11.3. Market Value Forecast, by Country/Sub-region, 2017–2028
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Indication
11.4.2. By Country/Sub-region
12. Middle East & Africa Companion Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2028
12.2.1. Breast Cancer
12.2.2. Lung Cancer
12.2.3. Colorectal Cancer
12.2.4. Gastric Cancer
12.2.5. Melanoma
12.2.6. Others (HIV, Thalassemia)
12.3. Market Value Forecast, by Country/Sub-region, 2017–2028
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Indication
12.4.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player – Competition Matrix (by tier and size of companies)
13.2. Market Share Analysis, by Company, 2020
13.3. Company Profiles
13.3.1. Labcorp Drug Development
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Financial Overview
13.3.1.3. Product Portfolio
13.3.1.4. Strategic Overview
13.3.1.5. SWOT Analysis
13.3.2. Agilent Technologies
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Financial Overview
13.3.2.3. Product Portfolio
13.3.2.4. Strategic Overview
13.3.2.5. SWOT Analysis
13.3.3. Myriad Genetic Laboratories, Inc.
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Financial Overview
13.3.3.3. Product Portfolio
13.3.3.4. Strategic Overview
13.3.3.5. SWOT Analysis
13.3.4. Qiagen
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Financial Overview
13.3.4.3. Product Portfolio
13.3.4.4. Strategic Overview
13.3.4.5. SWOT Analysis
13.3.5. Roche Molecular Systems, Inc.
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Financial Overview
13.3.5.3. Product Portfolio
13.3.5.4. Strategic Overview
13.3.5.5. SWOT Analysis
13.3.6. Dako Inc.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Financial Overview
13.3.6.3. Product Portfolio
13.3.6.4. Strategic Overview
13.3.6.5. SWOT Analysis
13.3.7. Abbott
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Financial Overview
13.3.7.3. Product Portfolio
13.3.7.4. Strategic Overview
13.3.7.5. SWOT Analysis
13.3.8. Foundation Medicine, Inc.
13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.8.2. Financial Overview
13.3.8.3. Product Portfolio
13.3.8.4. Strategic Overview
13.3.8.5. SWOT Analysis
13.3.9. MolecularMD Corporation
13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.9.2. Financial Overview
13.3.9.3. Product Portfolio
13.3.9.4. Strategic Overview
13.3.9.5. SWOT Analysis
13.3.10. Ventana Medical Systems, Inc.
13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.10.2. Product Portfolio
13.3.10.3. Strategic Overview
13.3.11. Illumina, Inc.
13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.11.2. Product Portfolio
13.3.11.3. Strategic Overview
13.3.11.4. SWOT Analysis
13.3.12. Life Technologies Corporation
13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.12.2. Product Portfolio
13.3.12.3. Strategic Overview
13.3.12.4. SWOT Analysis
13.3.13. Invivoscribe Technologies, Inc.
13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.13.2. Product Portfolio
13.3.13.3. Strategic Overview
13.3.13.4. SWOT Analysis
13.3.14. ARUP Laboratories, Inc.
13.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.14.2. Product Portfolio
13.3.14.3. Strategic Overview
13.3.14.4. SWOT Analysis
13.3.15. Leica Biosystems
13.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.15.2. Product Portfolio
13.3.15.3. Strategic Overview
13.3.15.4. SWOT Analysis
13.3.16. Biogenex Laboratories, Inc.
13.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.16.2. Product Portfolio
13.3.16.3. Strategic Overview
13.3.16.4. SWOT Analysis
13.3.17. bioMérieux, Inc.
13.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.17.2. Product Portfolio
13.3.17.3. Strategic Overview
13.3.17.4. SWOT Analysis
13.3.18. GE Healthcare
13.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.18.2. Product Portfolio
13.3.18.3. Strategic Overview
13.3.18.4. SWOT Analysis
13.3.19. Agendia N.V
13.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.19.2. Product Portfolio
13.3.19.3. Strategic Overview
13.3.19.4. SWOT Analysis
13.3.20. Exact Sciences Corp
13.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.20.2. Product Portfolio
13.3.20.3. Strategic Overview
13.3.20.4. SWOT Analysis
13.3.21. Genomic Health
13.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.21.2. Product Portfolio
13.3.21.3. Strategic Overview
13.3.21.4. SWOT Analysis
Table 01: Global Companion Diagnostics Value (US$ Mn) Forecast, by Indication, 2017–2028
Table 02: Global Companion Diagnostics Value (US$ Mn) Forecast, by Region, 2017–2028
Table 03: North America Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028
Table 04: North America Companion Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2028
Table 05: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028
Table 06: Europe Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 07: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028
Table 08: Asia Pacific Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 09: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028
Table 10: Latin America Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 11: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, by Indication, 2017–2028
Table 12: Middle East & Africa Companion Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028